Filing Details
- Accession Number:
- 0001209191-23-051898
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-10-04 16:07:56
- Reporting Period:
- 2023-10-02
- Accepted Time:
- 2023-10-04 16:07:56
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1649094 | Vaxcyte Inc. | PCVX | Biological Products, (No Disgnostic Substances) (2836) | 464233385 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1918033 | Mikhail Eydelman | C/O Vaxcyte, Inc. 825 Industrial Road, Suite 300 San Carlos CA 94070 | Svp, Gen Counsel & Corp Sec | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-10-02 | 20,000 | $21.41 | 40,487 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2023-10-02 | 7,992 | $49.58 | 32,495 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-10-02 | 4,874 | $50.22 | 27,621 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-10-02 | 7,134 | $51.44 | 20,487 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2023-10-02 | 20,000 | $0.00 | 20,000 | $21.41 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 205,000 | 2032-05-08 | No | 4 | M | Direct |
Footnotes
- The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 29, 2023.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $48.94 to $49.93. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $49.94 to $50.675. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The price reported is a weighted-average price. The shares were sold at prices ranging from $50.97 to $51.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- 1/4 of the shares subject to the option shall vest on April 1, 2023, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.
Billionaire Hedge Funds
